Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Lawrence I. Karsh, Edward Uchio, Brad Rosbrook, Yiyun Tang et al.
Journal
The Journal of Urology
Topics
Prostate Cancer Treatment and Research
article
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points
Lawrence I. Karsh, Edward Uchio, Brad Rosbrook, Yiyun Tang, Stephen J. Freedland, M. Backhaus, J. Kliment, Stéphane Supiot, Fabian Zohren, Ronald Tutrone, Gavin M. Marx, Ugo De Giorgi, Jamal Tarazi, Neal D. Shore, Erik P.M. Roos, Gabriel P. Haas, James L. Bailen, Matt Rosales
article en
Abstract
No abstract available for this paper.
Publication Tag
The Journal of UrologyVol. 215(4)
Institutions
Australian National University (AU), Cedars-Sinai Medical Center (US), Pfizer (United States) (US), Sydney Adventist Hospital (AU), Denver Health Medical Center (US), ImmunoGen (United States) (US), University of California, Irvine Medical Center (US), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Fundación Instituto Valenciano de Oncología (ES), St. Antonius Ziekenhuis (NL), Institut de Cancérologie de l'Ouest (FR), Model Clinical Research (US), Durham VA Medical Center (US), Energy Delivery Solutions (United States) (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Carolina Urologic Research Center (US), Astellas Pharma (United States) (US), Martin University Hospital (SK), Towson University (US), University of Colorado Denver (US)